| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Novavax Inc (NVAX) has 8 insiders with recent SEC Form 4 filings, including 5 buys and 6 sells. NVAX is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 264.1K | $2.46M | - | |
| CFO | 145.1K | $1.35M | - | |
| VP | 112.7K | $1.05M | - | |
| VP | 34.9K | $325.2K | - | |
| Dir | 28.5K | $265.7K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Aug 24, 2015 | Evans Gary C | Director | Sell | 20,000 | $11.24 | $224,808.00 | -5.5% | |
| Aug 20, 2015 | Phillips Barclay A | SVP, Chief Financial Officer | Sell | 28,656 | $13.06 | $374,323.37 | -50.3% | |
| Aug 18, 2015 | Glenn Gregory M88 | SVP, Research And Development | Sale+OE | 15,000 | $13.52 | $202,743.00 | -92.8% | |
| Aug 13, 2015 | Evans Gary C | Director | Sale+OE | 6,002 | $13.56 | $81,397.92 | -1.6% | |
| Jul 31, 2015 | Trizzino John86 | SVP, Commercial Operations | Buy | 5,098 | $3.63 | $18,505.74 | +17.8% | |
| Jul 31, 2015 | Herrmann John A III91 | SVP, General Counsel | Buy | 1,502 | $2.28 | $3,424.56 | +5.7% | |
| Jul 31, 2015 | Glenn Gregory M88 | SVP, Research And Development | Buy | 892 | $2.28 | $2,033.76 | +335.3% | |
| Jul 31, 2015 | Phillips Barclay A | SVP, Chief Financial Officer | Buy | 764 | $2.28 | $1,741.92 | +2.1% | |
| Jul 31, 2015 | Erck Stanley C86 | CEO And President | Buy | 3,207 | $2.28 | $7,311.96 | +3.3% | |
| Jun 18, 2015 | Young James F82 | Director | Sell | 50,000 | $9.47 | $473,615.00 | -11.8% |